Member Info for Laura2022

With all our USA clients like Bicycle and DoseMeRx you wonder whether PYC may consider dual listing down the line

Evening Cbeadle

Yes, shows what PYC can become a leader in its field

10 pence ( £15mln cap) is not beyond PYC

Hi Jungle

This is the start of a proper re valuation of PYC

Had you purchased any ?

"Limited time period "

The exclusivity provided has been extended for a limited time period until 31 December 2024 in exchange for a 0.5% equity interest in TheoremRx following the potential reversal into a US listed shell.

Do people actually read RNS

It clearly says what Mark will do with TRX

Last chance to buy ?

Yet can sell 1.25mln above the bidding price

£1000 only available

NT to buy for 4hrs now !!

All today

Ralph

Would also fit as Bicycle are NASDAQ listed and wll known and long term client

Full ask 0.75P or NT

Absolutely hopist

Pete has completely transformed the business in just 9mths

Look at TRAK....£500k salary..for nothing

Pete takes just £72k compared to average AIM salary of £250k

Quite rightly so

PYC should be 5-10p based on peer values

Nt to buy at 0.65p

Nothing available

More than £2k

£1k is full ask 0.7p

£2k NT

KingHomerJ

Posted in: PYC

Posts: 1,658

Price: 0.70

No Opinion

RE: 0.811 Oct 2024 14:05

PYC are in the best position they ever have been.

The New CEO Pete is very driven and has an exceptional background.

The revenue is the highest it ever has been going into a new financial year with the biggest pipeline with contracted revenues up until 2027...This alone warrants a MC in the multiples of current

The new biostats (new revenue stream) can itself produce far greater revenues that the current VT tech. (see recent presentation) Again multiples on the multiples

The Dosing tool which effectively is in two trials with NHS- Beyond Blood & Dosemerx in the US has the potential to add tens of Millions in revenue with the sheer saving it would save on the Docetaxel (Taxotere) Chemo

Docetaxel is a blockbuster cancer drug with peak global sales of £3.1 Billion and rising

PYC no debt

Tiny losses

Smallest CEO salary on AIM ( £72k v £250k+ average)

Revenues nearly higher than the cap

Just needs a £1.3mln revs ( pyc already on £900k with 8mths to go )

Soulac

Was a brilliant interview .. click on Trench123 name for a nice summary

As no stock